Arcus Biosciences, Inc. (RCUS)

USD 7.85

(-0.13%)

Net Debt Summary of Arcus Biosciences, Inc.

Arcus Biosciences, Inc.'s latest annual net debt in 2023 was -116 Million USD , down -34.88% from previous year.
Arcus Biosciences, Inc.'s latest quarterly net debt in 2024 Q1 was -174 Million USD , down -50.0% from previous quarter.
Arcus Biosciences, Inc. reported annual net debt of -86 Million USD in 2022, down -177.18% from previous year.
Arcus Biosciences, Inc. reported annual net debt of -31.02 Million USD in 2021, up 80.38% from previous year.
Arcus Biosciences, Inc. reported quarterly net debt of -145 Million USD for 2024 Q2, up 16.67% from previous quarter.
Arcus Biosciences, Inc. reported quarterly net debt of -175 Million USD for 2023 Q3, down -53.51% from previous quarter.

Annual Net Debt Chart of Arcus Biosciences, Inc. (2023 - 2016)

Historical Annual Net Debt of Arcus Biosciences, Inc. (2023 - 2016)

Year	Net Debt	Net Debt Growth
2023	-116 Million USD	-34.88%
2022	-86 Million USD	-177.18%
2021	-31.02 Million USD	80.38%
2020	-158.17 Million USD	-173.01%
2019	-57.93 Million USD	18.47%
2018	-71.06 Million USD	27.8%
2017	-98.42 Million USD	-51.05%
2016	-65.16 Million USD	0.0%

Year	Net Debt	Net Debt Growth
2024 Q1	-174 Million USD	-50.0%
2024 Q2	-145 Million USD	16.67%
2023 Q3	-175 Million USD	-53.51%
2023 FY	-116 Million USD	-34.88%
2023 Q1	-118 Million USD	-37.21%
2023 Q2	-114 Million USD	3.39%
2023 Q4	-116 Million USD	33.71%
2022 FY	-86 Million USD	-177.18%
2022 Q3	-98.45 Million USD	34.92%
2022 Q2	-151.28 Million USD	65.14%
2022 Q4	-86 Million USD	12.65%
2022 Q1	-433.96 Million USD	-1298.68%
2021 Q2	-270.74 Million USD	27.91%
2021 FY	-31.02 Million USD	80.38%
2021 Q4	-31.02 Million USD	76.22%
2021 Q3	-130.48 Million USD	51.8%
2021 Q1	-375.55 Million USD	-137.43%
2020 FY	-158.17 Million USD	-173.01%
2020 Q3	-221.84 Million USD	22.21%
2020 Q4	-158.17 Million USD	28.7%
2020 Q2	-285.18 Million USD	-323.59%
2020 Q1	-67.32 Million USD	-16.21%
2019 Q2	-76.06 Million USD	-11.05%
2019 FY	-57.93 Million USD	18.47%
2019 Q3	-78.99 Million USD	-3.84%
2019 Q1	-68.49 Million USD	3.61%
2019 Q4	-57.93 Million USD	26.65%
2018 Q2	-169.99 Million USD	14.19%
2018 FY	-71.06 Million USD	27.8%
2018 Q4	-71.06 Million USD	5.11%
2018 Q3	-74.88 Million USD	55.95%
2018 Q1	-198.11 Million USD	-101.28%
2017 Q1	98.89 Million USD	0.0%
2017 Q4	-98.42 Million USD	0.0%
2017 FY	-98.42 Million USD	-51.05%
2016 FY	-65.16 Million USD	0.0%

Peer Net Debt Comparison of Arcus Biosciences, Inc.

Name	Net Debt	Net Debt Difference
ADC Therapeutics SA	-154.22 Million USD	24.783%
Alto Neuroscience, Inc.	68.91 Million USD	268.323%
Annovis Bio, Inc.	-5.75 Million USD	-1915.737%
Biohaven Pharmaceutical Holding Company Ltd.	-218.84 Million USD	46.994%
Ginkgo Bioworks Holdings, Inc.	-707.09 Million USD	83.595%
Nuvation Bio Inc.	-38.64 Million USD	-200.191%
Nuvation Bio Inc.	-38.64 Million USD	-200.191%
Zymeworks Inc.	-130.83 Million USD	11.339%